James K. Sheffield

Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial

Ludwig Kappos, Krzysztof Selmaj, Amit Bar‐Or et al. · The Lancet Neurology · 2019 · 276 citations

Clinical Trials, Treatment Option, Pharmacotherapy +5

Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial

Jeffrey A. Cohen, Krzysztof Selmaj, Amit Bar‐Or et al. · The Lancet Neurology · 2019 · 270 citations

Neurological Progress, Clinical Trials, Clinical Neurology +6

Motor overflow and mirror dystonia

Oraporn Sitburana, Laura Wu, James K. Sheffield et al. · Parkinsonism & Related Disorders · 2009 · 62 citations

Degenerative Diseases, Motor System, Motor Control +8

Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial

Bruce Cree, Krzysztof Selmaj, Lawrence Steinman et al. · Multiple Sclerosis Journal · 2022 · 45 citations · Full text

Comparative safety and efficacy of ozanimod versus fingolimod for relapsing multiple sclerosis

Elyse Swallow, Oscar Patterson‐Lomba, Lei Yin et al. · Journal of Comparative Effectiveness Research · 2020 · 44 citations · Full text